21st Century Cures Act: A Boon For Drug Companies, Research Programs
NPR
Wednesday, December 7, 2016
Update RequiredTo play audio, update browser or
Flash plugin.
House Majority Leader Kevin McCarthy of Calif., left, shakes hands with Rep. Tim Murphy, R-Pa., center, and Rep. Fred Upton, R-Mich., right, during a news conference on Capitol Hill in Washington, Wednesday, Nov. 30, 2016. (Susan Walsh/AP)
The Senate is expected to vote this afternoon on the 21st Century Cures Act. It is considered landmark legislation that would provide funding for research programs like Vice President Joe Biden’s moonshot against cancer.
It will also make significant changes in how drugs are tested and approved.
The act passed in the House overwhelmingly and is expected to easily pass the Senate as well.
NPR’s Richard Harris (@rrichardh) joins Here & Now‘s Jeremy Hobson to discuss what this legislation will mean for drug companies, medical research and more.
Copyright 2024 NPR. To see more, visit https://www.npr.org.
View this story on npr.org
Follow us for more stories like this
CapRadio provides a trusted source of news because of you. As a nonprofit organization, donations from people like you sustain the journalism that allows us to discover stories that are important to our audience. If you believe in what we do and support our mission, please donate today.
Donate Today